Collection of Samples USOPTIVAL Study
Study Details
Study Description
Brief Summary
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination.
Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Arm A. Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery |
Diagnostic Test: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Evaluate the performance of a preliminary panel of biomarkers
|
| Arm B Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy |
Diagnostic Test: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Evaluate the performance of a preliminary panel of biomarkers
|
Outcome Measures
Primary Outcome Measures
- Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing [Within 12 months of sample collection]
Samples Collected for Testing
Eligibility Criteria
Criteria
Inclusion Criteria:
Arm A:
-
Must be 45-84 years of age.
-
Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery.
-
Able to comprehend, sign, and date the written informed consent document.
Arm B:
-
Must be 45-84 years of age.
-
Able and willing to undergo a standard-of-care screening colonoscopy within 60 days.
-
Able to comprehend, sign, and date the written informed consent document.
Exclusion Criteria:
Arm A Only:
- Subject with curative biopsy during colonoscopy.
Arm B Only:
-
Subjects with positive FIT Test results in the 6 months preceding enrollment.
-
Subject has a current diagnosis of cancer.
Arms A & B:
-
Subject has a personal history of aerodigestive or digestive tract cancers.
-
Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer.
-
Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer:
-
Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
-
Familial adenomatous polyposis ("FAP", including attenuated FAP).
-
Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome").
-
Serrated polyposis syndrome
-
2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer.
-
One first-degree relative with CRC diagnosed before the age of 60.
-
A significant disease which, in the Investigator's opinion, would exclude the subject from the study.
-
Legal incapacity or limited mental capacity.
-
Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent.
-
The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions.
-
The patient is known to be pregnant when recruited or during her participation in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Precision Recearch Institute | Chula Vista | California | United States | 91910 |
| 2 | Precision Research Institute | San Diego | California | United States | 92114 |
| 3 | Medical Associates Research Group | San Diego | California | United States | 92123 |
| 4 | Clinical Research of California | Walnut Creek | California | United States | 94598 |
| 5 | Center for Gastrointestinal Disorders | Hollywood | Florida | United States | 33021 |
| 6 | Lakeland Regional Cancer Center | Lakeland | Florida | United States | 33805 |
| 7 | Springfield Clinic | Springfield | Illinois | United States | 62702 |
| 8 | Ochsner Clinic | New Orleans | Louisiana | United States | 70121 |
| 9 | Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
| 10 | Mid Hudson Medical Research | New Windsor | New York | United States | 12553 |
| 11 | University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
| 12 | Fox Chase Cancer Center | Philadelphia | Pennsylvania | United States | 19111 |
| 13 | Frontier Clinical Research | Uniontown | Pennsylvania | United States | 15401 |
| 14 | Clinical Trials Network | Union City | Tennessee | United States | 38261 |
| 15 | Vilo Research Group | Houston | Texas | United States | 77017 |
| 16 | Gastroenterology Consultants of SW Virginia | Roanoke | Virginia | United States | 24014 |
Sponsors and Collaborators
- Universal Diagnostics
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CRC-US-001